Clinical Trial

Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.

Study acronym: FUTURE-3
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
FUTURE-3 was a prospective, multicenter, single-arm phase II study designed to explore the efficacy and safety of MRI-guided individualized chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. The primary endpoint was one-year progression-free survival rate.
Trial Details
NCT Number NCT07469241
Lead Sponsor Fudan University
Conditions Advanced Esophageal Squamous Cell Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma
Enrollment 50 participants
Start Date 2026-03-10
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-13